Deal Making

Featured on Deal Making

Regeneron forks out $250m to buy Checkmate Pharmaceuticals
Deal-Making
Regeneron forks out $250m to buy Checkmate PharmaceuticalsRegeneron forks out $250m to buy Checkmate Pharmaceuticals

Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals.

More from Deal Making